Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.1.1 Higher growth rate and incidences of cancer
4.1.2 Enlargement of private diagnostic centres
4.1.3 Funding and Awareness programmes
4.1.4 Population growth
4.2 Restraints
4.2.1 Expensive diagnostic procedures
4.2.2 Lack of Skilled Persons
4.2.3 Regulations imposed by Authorities
4.2.4 Lack Modern Equipment’s and procedures
4.3 Opportunities
4.3.1 Miniaturized advanced devices
4.3.2 Research organisation and imminent Health Revolution
4.3.3 Improving Infrastructure and tourism
4.4 Challenges
4.4.1 Rivalry among competitors
4.4.2 No proper access to cancer detection
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation by Type
6.1 Introduction
6.2 Platform based
6.2.1 Polymerase chain reaction
6.2.2 Insitu Hybridization
6.2.3 Immuno Histo Chemistry
6.2.4 Next generation sequencing
6.2.5 DNA microarrays
6.2.6 Flow cytometry
6.2.7 Other technologies
6.3 Instrument based
6.3.1 Imaging
6.3.2 Magnetic resonance Imaging
6.3.3 CT (Computed Tomography)
6.3.4 Positron emission tomography
6.3.4.1 Standalone positron emission tomography
6.3.4.2 Hybrid positron emission tomography
6.3.5 Mammography
6.3.6 Ultrasound
6.3.7 Biopsy
Chapter 7 Market Segmentation by Application
7.1 Introduction
7.1.1 Lung cancer
7.1.2 Breast cancer
7.1.3 Colorectal cancer
7.3.4 Melanoma
7.3.5 Other Cancers
Chapter 8 Market Segmentation by Geography
8.1 North America
8.1.1 Introduction
8.1.2 United States
8.1.3 Canada
8.1.4 Mexico
8.1.5 Others
8.2 Europe
8.2.1 Introduction
8.2.2 France
8.2.3 Germany
8.2.4 Italy
8.2.5 United Kingdom
8.2.6 Spain
8.2.7 Russia
8.2.8 Others
8.3 Asia-pacific
8.3.1 Introduction
8.3.2 China
8.3.3 Japan
8.3.4 India
8.3.5 Australia
8.3.6 Others
8.4 Latin America
8.4.1 Introduction
8.4.2 Brazil
8.4.3 Argentina
8.4.4 Others
8.5 The Middle East and Africa
8.5.1 Introduction
8.5.2 Saudi Arabia
8.5.3 Israel
8.5.4 UAE
8.5.5 Others
Chapter 9 Competitive Landscape
9.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
9.2 Market Share Analysis
9.3 Strategies Adopted By Top Companies
Chapter 10 Company Profiles
10.1 GE healthcare
10.1.1 Business Overview
10.1.2 Product portfolio
10.1.3 Key Strategy
10.1.4 Recent Developments
10.2 Abbott
10.3 Agilent technologies
10.4 Becton, Dickinson Company
10.5 Roche
10.6 Illumina Inc
10.7 Hologic Inc
10.8 Siemens Healthcare
10.9 Qiagen
10.10 Thermo Fisher scientific
10.11 C.R.Bard Inc
10.12 Koninklijke Philips N.V
10.13 Genomic Health
10.14 NanoString Technologies
10.15 Oxford Gene Technology
Chapter 11 Market Estimates and Forecast
11.1 Market Estimates and forecast 2018-2024(USD million)
11.1.1 Market Estimates and forecast by type 2018-2024(USD million)
11.1.2 Market Estimates and forecast by Application 2018-2024(USD million)
11.1.3 Market Estimates and forecast by geography 2018-2024(USD million)
11.1.4 Market Estimates and forecast by company Profiles 2018-2024(USD million)
Chapter 12 Market Insights
12.1 Insights of Industry Experts
12.2 Analyst Opinion (Market Understanding)
12.3 Investment Opportunities
Chapter 13 Appendix
13.1 List of Tables
13.2 List of Figures
